Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway [Yahoo! Finance]
Hoth Therapeutics, Inc. (HOTH)
Company Research
Source: Yahoo! Finance
NEW YORK Oct. 15, 2024 HT-ALZ represents a breakthrough in Alzheimer's treatment, specifically targeting the Substance P/Neurokinin-1 Receptor pathway. This pathway is known to play a critical role in neuroinflammation, which is increasingly recognized as a driving factor in the progression of Alzheimer's disease. Preclinical studies have shown promising results, including reduced neuroinflammation and significant improvements in cognitive functions such as memory and learning. The patent solidifies Hoth's leadership in the development of Alzheimer's therapies and paves the way for the next phase of human clinical trials. Formulation of HT-ALZ for these trials is currently underway, with the goal of advancing this promising treatment to patients as swiftly as possible. Next Steps As Hoth Therapeutics completes the formulation phase, the company will look to prepare clinical trials to further validate HT-ALZ's efficacy in humans. The upcoming trials will focus on demonstrating
Show less
Read more
Impact Snapshot
Event Time:
HOTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOTH alerts
High impacting Hoth Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOTH
News
- Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
- Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic [Yahoo! Finance]Yahoo! Finance
- Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer TherapeuticPR Newswire
- Hoth Therapeutics regains compliance with Nasdaq [Seeking Alpha]Seeking Alpha
- Hoth Therapeutics Regains Compliance with Nasdaq Listing RequirementsPR Newswire
HOTH
Analyst Actions
- 1/23/25 - HC Wainwright
HOTH
Sec Filings
- 2/7/25 - Form 8-K
- 2/7/25 - Form 424B5
- 1/24/25 - Form 8-K
- HOTH's page on the SEC website